Pharmacogenetics of Dipeptidyl Peptidase 4 Inhibitors in a Taiwanese Population with Type 2 Diabetes

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Feb 5

PMID 28160554

Citations 8

Authors

Wen-Ling Liao

Wen-Jane Lee

Ching-Chu Chen

Chieh Hsiang Lu

Chien-Hsiun Chen

Yi-Chun Chou

I-Te Lee

Wayne H-H Sheu

Jer-Yuarn Wu

Chi-Fan Yang

Chung-Hsing Wang

Fuu-Jen Tsai

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors' advantages, the patients' therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classified as sensitive or resistant to treatment based on the mean change in HbA1c levels. Using an assumption-free genome-wide association study, 45 single nucleotide polymorphisms (SNPs) involved in the therapeutic response to DPP-4 inhibitors (P < 1 × 10-4) were identified at or near PRKD1, CNTN3, ASK, and LOC10537792. A SNP located within the fourth intron of PRKD1 (rs57803087) was strongly associated with DPP-4 inhibitor response (P = 3.2 × 10-6). This is the first pharmacogenomics study on DPP-4 inhibitor treatment for diabetes in a Taiwanese population. Our data suggest that genes associated with β-cell function and apoptosis are involved in the therapeutic effect of DPP-4 inhibitors, even in the presence of additional oral anti-diabetic drugs. Our findings provide information on how genetic variants influence drug response and may benefit the development of personalized medicine.

Citing Articles

Effects of Different Cow-Milk Beta-Caseins on the Gut-Brain Axis: A Narrative Review of Preclinical, Animal, and Human Studies.

Robinson S, Greenway F, Deth R, Fayet-Moore F Nutr Rev. 2024; 83(3):e1259-e1269.

PMID: 39024213 PMC: 11819488. DOI: 10.1093/nutrit/nuae099.

Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.

Eghbali M, Alaei-Shahmiri F, Hashemi-Madani N, Emami Z, Mostafavi L, Malek M Adv Ther. 2024; 41(2):826-836.

PMID: 38172377 DOI: 10.1007/s12325-023-02761-1.

Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice.

Venkatachalapathy P, Padhilahouse S, Sellappan M, Subramanian T, Kurian S, Miraj S Pharmgenomics Pers Med. 2021; 14:1441-1455.

PMID: 34803393 PMC: 8598203. DOI: 10.2147/PGPM.S329787.

Pharmacogenetics of new classes of antidiabetic drugs.

Imamovic Kadric S, Kulo Cesic A, Dujic T Bosn J Basic Med Sci. 2021; 21(6):659-671.

PMID: 33974529 PMC: 8554705. DOI: 10.17305/bjbms.2021.5646.

Pharmacogenetics of novel glucose-lowering drugs.

Rathmann W, Bongaerts B Diabetologia. 2021; 64(6):1201-1212.

PMID: 33594477 PMC: 8099830. DOI: 10.1007/s00125-021-05402-w.

References

Omar B, Vikman J, Winzell M, Voss U, Ekblad E, Foley J . Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia. 2013; 56(8):1752-60. DOI: 10.1007/s00125-013-2927-8. View

McIntosh C, Widenmaier S, Kim S . Glucose-dependent insulinotropic polypeptide signaling in pancreatic β-cells and adipocytes. J Diabetes Investig. 2014; 3(2):96-106. PMC: 4020726. DOI: 10.1111/j.2040-1124.2012.00196.x. View

Cordero O, Salgado F, Nogueira M . On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009; 58(11):1723-47. PMC: 11031058. DOI: 10.1007/s00262-009-0728-1. View

. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44(11):1249-58. View

Lim S, An J, Shin H, Khang A, Lee Y, Ahn H . Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf). 2011; 77(2):215-23. DOI: 10.1111/j.1365-2265.2011.04240.x. View

Yazbeck R, Howarth G, Abbott C . Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol Sci. 2009; 30(11):600-7. DOI: 10.1016/j.tips.2009.08.003. View

Kong K, Butcher A, McWilliams P, Jones D, Wess J, Hamdan F . M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. Proc Natl Acad Sci U S A. 2010; 107(49):21181-6. PMC: 3000281. DOI: 10.1073/pnas.1011651107. View

Bian L, Hanson R, Ossowski V, Wiedrich K, Mason C, Traurig M . Variants in ASK1 are associated with skeletal muscle ASK1 expression, in vivo insulin resistance, and type 2 diabetes in Pima Indians. Diabetes. 2010; 59(5):1276-82. PMC: 2857909. DOI: 10.2337/db09-1700. View

Leibowitz G, Cahn A, Bhatt D, Hirshberg B, Mosenzon O, Wei C . Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. Diabetes Obes Metab. 2015; 17(5):487-94. DOI: 10.1111/dom.12445. View

10.

Widenmaier S, Ao Z, Kim S, Warnock G, McIntosh C . Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem. 2009; 284(44):30372-82. PMC: 2781592. DOI: 10.1074/jbc.M109.060178. View

11.

Yamagishi S, Matsui T . Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 2011; 17(38):4379-85. DOI: 10.2174/138161211798999456. View

12.

Campbell J, Drucker D . Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17(6):819-837. DOI: 10.1016/j.cmet.2013.04.008. View

13.

Scheen A . Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010; 49(9):573-88. DOI: 10.2165/11532980-000000000-00000. View

14.

Kim S, Shim W, Lee E, Lee Y, Beom S, Kim E . Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus. Diabetes Metab J. 2011; 35(2):159-65. PMC: 3122893. DOI: 10.4093/dmj.2011.35.2.159. View

15.

Kim W, Egan J . The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4):470-512. PMC: 2696340. DOI: 10.1124/pr.108.000604. View

16.

H Ahmed R, Huri H, Al-Hamodi Z, Salem S, Al-Absi B, Muniandy S . Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects. PLoS One. 2016; 11(4):e0154369. PMC: 4844141. DOI: 10.1371/journal.pone.0154369. View

17.

Liao W, Tsai F . Personalized medicine in Type 2 Diabetes. Biomedicine (Taipei). 2014; 4:8. PMC: 4264975. DOI: 10.7603/s40681-014-0008-z. View

18.

Eiseler T, Doppler H, Yan I, Kitatani K, Mizuno K, Storz P . Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat Cell Biol. 2009; 11(5):545-56. PMC: 2761768. DOI: 10.1038/ncb1861. View

19.

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

20.

Hayakawa R, Hayakawa T, Takeda K, Ichijo H . Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(8):434-53. PMC: 3491083. DOI: 10.2183/pjab.88.434. View